comparision between intratracheal vs intravenous dexmedetomidine during tracheal extubation under general anaesthesia

A Prospective Randomized Comparative Study to Compare the Efficacy of Intratracheal Dexmedetomidine versus Intravenous Dexmedetomidine in Attenuating Periextubation Cough and Hemodynamic Stress Response during Tracheal Extubation under General Anaesthesia - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/01/078858

Enrollment

Registered

2025-01-16

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Intra Tracheal Dexmedetomidine 0.3mcg/kg: Intra Tracheal Dexmedetomidine 0.3 mcg/kg (diluted till 1 ml) 30 minutes prior to tracheal extubation of general anaesthesia Control Interventi

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients voluntarilly willing to sign informed consent. 2. Male or female patients between 18 to 60 years of age. 3. Patients belonging to American Society of Anesthesiologists (ASA) physical status I and II. 4. Patients posted for elective surgeries under general anaesthesia

Exclusion criteria

Exclusion criteria: 1. Patients unwilling to participate in the study. 2. Patients with American society of Anesthesiiologist (ASA) physical status III, IV, V 3. Patients with Body Mass Index = 30 kg/m2 4. Patients with anticipated difficult airway& intubation. 5. Patient with preexisting hoarseness or sore throat or upper respiratory tract infection. 6. Patients with cardiovascular diseases, arrhythmias, heart blocks, or taking beta blockers or any antihypertensive treatment. 7. Patients with cerebrovascular, hepatic and renal diseases. 8. Patient using steroids or having history of asthma or COPD. 9. Patients with history of allergy to an a-2 adrenergic agonist 10. Pregnancy & lactating women.

Design outcomes

Primary

Measure	Time frame
To study the efficacy of attenuating peri-extubation cough using 4 point cough scale during tracheal extubationTimepoint: At time of awareness At time of Extubation After extubation At 1 min At 2 min At 3 min At 5 min	—

Secondary

Measure	Time frame
To study the post operative sedation scoreTimepoint: Ramsay Sedation Score (RSS) will be recorded till the patient achieve RSScore 2;To study the haemodynamic stress responses during extubationTimepoint: Preoperative After induction At laryngoscopy At intubation 5 min before drug administration At time of drug administration aftrer drug administration At 5 mins after drug AT 10 mins after drug At the end of surgery At point of awarness During Extubation After extubation At 2 min At 5 min At 15 min At 30 min;To study the duration of analgesia by Visual Analogue Score (VAS) score and side effects if anyTimepoint: VAS will be recorded till the patient achieves VAS 4	—

Measure

Time frame

To study the post operative sedation scoreTimepoint: Ramsay Sedation Score (RSS) will be recorded till the patient achieve RSScore 2;To study the haemodynamic stress responses during extubationTimepoint: Preoperative After induction At laryngoscopy At intubation 5 min before drug administration At time of drug administration aftrer drug administration At 5 mins after drug AT 10 mins after drug At the end of surgery At point of awarness During Extubation After extubation At 2 min At 5 min At 15 min At 30 min;To study the duration of analgesia by Visual Analogue Score (VAS) score and side effects if anyTimepoint: VAS will be recorded till the patient achieves VAS 4

—

Countries

India

Contacts

Public ContactDr Jatin Patel

Smt.Bhikhiben Kanjibhai Shah Medical Institute & Research Centre

dr_jatinpatel@yahoo.co.in9879368363

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026